Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and safety of Meningococcal vaccine GSK 134612 when co-administered with pneumococcal and DTPa-HBV-IPV/Hib vaccines;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK 134612

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal, Meningococcal Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2019-02-01